BRCA1 and ovarian carcinoma: According to Polish guidelines, a panel of these five founder mutations of BRCA1 is used as an initial screening tool for all patients with breast cancer and/or ovarian cancer, and healthy individuals with a family history of at least breast and/or ovarian cancer.